Although epilepsy is first known as a disease of seizures and convulsions,most patients with epilepsy also suffer from seizure-associated behavioral abnormalities in motor functions,psychiatric status,and cognition.Th...Although epilepsy is first known as a disease of seizures and convulsions,most patients with epilepsy also suffer from seizure-associated behavioral abnormalities in motor functions,psychiatric status,and cognition.These neurobehavioral comorbidities may have greater impacts on the quality of life of people with epilepsy than the seizures themselves and can profoundly interfere with the treatment compliance.While repeated seizures often lead to behavioral comorbidities,certain types of comorbid conditions may potentially increase the risk for epileptic seizures,indicative of some common mechanisms that might underlie these two conditions.As such,emerging evidence supports that inflammation within the brain might represent a key component of such a shared mechanism,given that neuroinflammation can be induced by seizures and various behavioral stressors,and in turn may exacerbate both conditions.Among inflammatory pathways that arise after prolonged seizures,PGE_(2) signaling via the EP2 receptor promotes cytokine induction,blood–brain barrier disruption,reactive gliosis,neuronal death,and eventually,contributes to behavioral dysfunctions.Pharmacological inhibition of EP2 by small-molecule drug-like antagonists affords broad therapeutic benefits including anti-inflammatory and neuroprotective effects in several rodent seizure models,leading to long-lasting alleviation of neurobehavioral comorbidities,particularly cognitive impairments.Targeting this key inflammatory prostaglandin receptor might provide an adjunctive strategy,along with the current anti-seizure medications,to mitigate cognitive dysfunctions associated with seizure disorders.展开更多
基金supported by the National Institutes of Health(NIH)/National Institute of Neurological Disorders and Stroke(NINDS)grants(USA)R01NS100947(Jianxiong Jiang)R21NS136070(Jianxiong Jiang)R61NS130199(Jianxiong Jiang and Jiawang Liu).
文摘Although epilepsy is first known as a disease of seizures and convulsions,most patients with epilepsy also suffer from seizure-associated behavioral abnormalities in motor functions,psychiatric status,and cognition.These neurobehavioral comorbidities may have greater impacts on the quality of life of people with epilepsy than the seizures themselves and can profoundly interfere with the treatment compliance.While repeated seizures often lead to behavioral comorbidities,certain types of comorbid conditions may potentially increase the risk for epileptic seizures,indicative of some common mechanisms that might underlie these two conditions.As such,emerging evidence supports that inflammation within the brain might represent a key component of such a shared mechanism,given that neuroinflammation can be induced by seizures and various behavioral stressors,and in turn may exacerbate both conditions.Among inflammatory pathways that arise after prolonged seizures,PGE_(2) signaling via the EP2 receptor promotes cytokine induction,blood–brain barrier disruption,reactive gliosis,neuronal death,and eventually,contributes to behavioral dysfunctions.Pharmacological inhibition of EP2 by small-molecule drug-like antagonists affords broad therapeutic benefits including anti-inflammatory and neuroprotective effects in several rodent seizure models,leading to long-lasting alleviation of neurobehavioral comorbidities,particularly cognitive impairments.Targeting this key inflammatory prostaglandin receptor might provide an adjunctive strategy,along with the current anti-seizure medications,to mitigate cognitive dysfunctions associated with seizure disorders.
